Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for HCV genotype 1b patients

Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for HCV genotype 1b patients
复制标题

DOI：
10.1111/j.1478-3231.2011.02727.x
复制
发表时间：
2012-05
期刊：
Liver International
影响因子：
6.7
通讯作者：
A. Tsubota;N. Shimada;K. Yoshizawa;Tomomi Furihata;R. Agata;Yoko Yumoto;H. Abe;Makiko Ika;Y. Namiki;K. Chiba;K. Fujise;N. Tada;Y. Aizawa
A. Tsubota;N. Shimada;K. Yoshizawa;Tomomi Furihata;R. Agata;Yoko Yumoto;H. Abe;Makiko Ika;Y. Namiki;K. Chiba;K. Fujise;N. Tada;Y. Aizawa
中科院分区：
医学2区
文献类型：
--
作者：
A. Tsubota;N. Shimada;K. Yoshizawa;Tomomi Furihata;R. Agata;Yoko Yumoto;H. Abe;Makiko Ika;Y. Namiki;K. Chiba;K. Fujise;N. Tada;Y. Aizawa

文献摘要

被引文献

相似文献

标准剂量利巴韦林对于慢性丙型肝炎病毒（HCV）感染的标准治疗至关重要。平衡型核苷转运蛋白1（ENT1）由SLC29A1基因编码，是将利巴韦林转运到人肝细胞的主要转运蛋白。目标：
Standard‐dose ribavirin is crucial for the standard‐of‐care treatment of chronic hepatitis C virus (HCV) infection. Equilibrative nucleoside transporter 1 (ENT1), encoded by SLC29A1 gene, is the main transporter that imports ribavirin into human hepatocytes. Aims: